While both EMT and ZEB1 has been found to medicate acquired resistance to EGFR inhibitors in non-small cell lung cancer34,35, our iGenSig signature suggested the discordance of ZEB1 overexpression with EMT induction and their differential contribution to Erlotinib resistance in Pan-cancer cell lines. The gene discussed is EGFR; the disease is cancer.